Tarlatumab (Potential Treatment for Rheumatoid Arthritis)
Tarlatumab is a monoclonal antibody currently under investigation as a potential treatment for rheumatoid arthritis (RA). It works by targeting a specific protein called interleukin-17 (IL-17), which plays a crucial role in the inflammation and joint damage associated with RA.
Working
- IL-17 Inhibition: Tarlatumab binds to IL-17, preventing it from interacting with its receptors and triggering inflammatory responses.
- Reduced Inflammation: By blocking IL-17, tarlatumab helps to reduce inflammation in the joints, potentially leading to improved symptoms and disease progression.